FDA Clearance Tracker · P190002-S001
Saluda Medical Evoke® SCS System
Last checked: Nov 20, 2026Latest source record: Oct 26, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Oct 26, 2022
Approved
Time to decision
237 days
Received Mar 3, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P190002-S001
- Device name
- Saluda Medical Evoke® SCS System
- Applicant
- Saluda Medical Pty, Ltd.
- Applicant location
- Atarmon
- Received
- Mar 3, 2022
- Decided
- Oct 26, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P190002
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval to move the current cleanroom facilities located at 14 Mars Rd, Lane Cove, NSW, Australia (Lane Cove) to 5 Eden Park Drive, Macquarie Park, NSW, Australia (Macquarie Park) and approval to duplicate external device production from the current Artarmon facility (407 Pacific Highway, Artarmon, NSW, Australia) to the Macquarie Park facility.
Source documents
Other decisions for Saluda Medical Pty, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Saluda Medical Evoke® SCS SystemPMA supplement
P190002-S019 · Decided Mar 20, 2024 · 180 days after receipt · Panel Track
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.